Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Immunovia AB

Ratings ESG MSCI

Ratings ESG MSCI - Immunovia AB

Ratings Immunovia AB: Strengths and Weaknesses

Highlights: Immunovia AB
  • The company's profit outlook over the next few years is a strong asset.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: Immunovia AB
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Rating Financials

Immunovia AB SectorUnited Kingdom

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

More ratings
Fundamental Rankings - Immunovia AB

Rating Valuation

Immunovia AB SectorUnited Kingdom

Global Valuation

-

Enterprise Value

-

EV/Revenue

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings
Fundamental Rankings - Immunovia AB

Rating Consensus

Immunovia AB SectorUnited Kingdom

Consensus

-

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

-

Analysts' recommendations evolution (4 months)

-

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings
Fundamental Rankings - Immunovia AB

Rating Business Predictability

Immunovia AB SectorUnited Kingdom

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

Fundamental Rankings - Immunovia AB

Rating Revisions

Immunovia AB SectorUnited Kingdom

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - Immunovia AB


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
4.35M - - - - - -
243B
BBB
152B
A
143B
BBB
61.14B
BBB
49.85B
AAA
47.74B
AAA
47.74B
BBB
45.9B
AAA
41.3B
A
Average 83.1B
AA
Weighted average by Cap.
AA